Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004853-59
    Sponsor's Protocol Code Number:EX6018-4758
    National Competent Authority:Croatia - MIZ
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2023-01-05
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedCroatia - MIZ
    A.2EudraCT number2020-004853-59
    A.3Full title of the trial
    ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
    ZEUS- Učinci ziltivekimaba u odnosu na placebo na kardiovaskularne ishode u ispitanika s potvrđenom aterosklerotskom kardiovaskularnom bolešću, kroničnom bolešću bubrega i sistemskom upalom
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    ZEUS – A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation
    ZEUS – Kliničko ispitivanje kojim se ispituje djelovanje ziltivekimaba u usporedbi s placebom kod ispitanika s kardiovaskularnim bolestima, kroničnom bubrežnom bolešću i sistemskom upalom
    A.4.1Sponsor's protocol code numberEX6018-4758
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1259-3422
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/498/2020
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovo Nordisk A/S
    B.1.3.4CountryDenmark
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovo Nordisk A/S
    B.4.2CountryDenmark
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovo Nordisk A/S
    B.5.2Functional name of contact pointClinical Transparency (2834)
    B.5.3 Address:
    B.5.3.1Street AddressNovo Allé
    B.5.3.2Town/ cityBagsværd
    B.5.3.3Post code2880
    B.5.3.4CountryDenmark
    B.5.6E-mailclinicaltrials@novonordisk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameZiltivekimab B 15 mg/mL DV3430-C1
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNN/A
    D.3.9.3Other descriptive nameZiltivekimab
    D.3.9.4EV Substance CodeSUB204133
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number15
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Atherosclerotic cardiovascular disease
    Chronic kidney disease
    Systemic inflammation
    Aterosklerotska kardiovaskularna bolest
    Kronićna bolest bubrega
    Sistemska upala
    E.1.1.1Medical condition in easily understood language
    Cardiovascular disease
    Chronic kidney disease
    Inflammation
    Kardiovaskularna bolest
    Kronićna bolest bubrega
    Upala
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10051615
    E.1.2Term Atherosclerotic cardiovascular disease
    E.1.2System Organ Class 100000004866
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.1
    E.1.2Level PT
    E.1.2Classification code 10064848
    E.1.2Term Chronic kidney disease
    E.1.2System Organ Class 10038359 - Renal and urinary disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10067394
    E.1.2Term hs-CRP increased
    E.1.2System Organ Class 100000004848
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10011418
    E.1.2Term CRP increased
    E.1.2System Organ Class 100000004848
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the superiority of ziltivekimab 15 mg s.c. once-monthly in reducing the risk of MACE (as defined by the primary endpoint) compared to placebo, both added to standard of care, in participants with established ASCVD, CKD and systemic inflammation.
    Dokazati superiornost ziltivekimaba (humano monoklonsko antitijelo na interleukin 6, IL-6) koji se primjenjuje subkutano jedanput mjesečno u dozi od 15 mg u smanjenju rizika od velikog štetnog kardiovaskularnog događaja (definirano kao primarna krajnja točka ispitivanja)u usporedbi s placebom, oba dodana standardnom liječenju, kod ispitanika s utvrđenim aterosklerotičnim kardiovaskularnim bolestima, kroničnim bolestima bubrega i sistemskom upalom.
    E.2.2Secondary objectives of the trial
    - To demonstrate the superiority of ziltivekimab 15 mg s.c. once-monthly compared to placebo, both added to standard of care, in participants with established ASCVD, CKD and systemic inflammation, with regards to the following:
    • reducing the risk of expanded MACE (as defined by the confirmatory secondary endpoint)
    • reducing the risk of heart failure (as defined by the confirmatory secondary endpoint)
    • reducing all-cause mortality
    • delaying the progression of CKD (as defined by the confirmatory secondary endpoint)
    - To compare the effects of ziltivekimab 15 mg s.c. once-monthly versus placebo, both added to standard of care, in participants with established ASCVD, CKD and systemic inflammation, with regards to the following:
    • reducing systemic inflammation (defined by the secondary and exploratory endpoints)
    • improving patient reported outcomes (PRO)
    • not increasing severe infections (as defined by secondary safety endpoints)
    Potvrda superiornosti ziltivekimaba koji se primjenjuje s.c. jedanput mjesečno u dozi od 15 mg u odnosu na placebo, oba dodana standardnoj terapiji, kod ispitanika s utvrđenim aterosklerotičnim kardiovaskularnim bolestima, kroničnim bolestima bubrega i sistemskom upalom obzirom na:
    •smanjenje rizika od proširenog velikog štetnog kardiovaskularnog događaja
    •smanjenje rizika od zatajenja srca
    •smanjenje mortaliteta bez obzira na uzrok
    •odgodu napredovanja kronične bubrežne bolesti
    -Usporedba učinaka ziltivekimaba koji se primjenjuje subkutano jedanput mjesečno u dozi od 15 mg u odnosu na placebo,oba dodana standardnoj terapiji, kod ispitanika s utvrđenim aterosklerotičnim kardiovaskularnim bolestima, kroničnim bolestima bubrega i sistemskom upalom obzirom na:
    •smanjenje sistemske upale
    •poboljšanje u ishodu liječenje iz perspektive ispitanika
    •ne povećanje teških infekcija
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    The title is the same as main title : 'ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation'.

    No new primary and secondary objectives added for the sub-study
    Naslov je isti kao i naslov glavnog ispitivanja: ZEUS- Učinci ziltivekimaba u odnosu na placebo na kardiovaskularne ishode u ispitanika s potvrđenom aterosklerotskom kardiovaskularnom bolešću, kroničnom bolešću bubrega i sistemskom upalom.

    Nema dodanih novih primarnih i sekundarnih ciljeva za podstudiju.
    E.3Principal inclusion criteria
    - eGFR greater than or equal to 15 and below 60 mL/min/1.73 m^2 (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation)
    - Serum hs-CRP greater than or equal to 2 mg/L at screening (visit 1)
    - Evidence of ASCVD by one or more of the following:
    a) Coronary heart disease defined as at least one of the following:
    i. Documented history of MI
    ii. Prior coronary revascularisation procedure
    iii. greater than or equal to 50% stenosis in major epicardial coronary artery documented by cardiac catheterisation or CT coronary angiography
    b) Cerebrovascular disease defined as at least one of the following:
    i. Prior stroke of atherosclerotic origin
    ii. Prior carotid artery revascularisation procedure
    iii. greater than or equal to 50% stenosis in carotid artery documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound.
    c) Symptomatic peripheral artery disease (PAD) defined as at least one of the following:
    i. Intermittent claudication with an ankle-brachial index (ABI) below or equal to 0.90 at rest
    ii. Intermittent claudication with a greater than or equal to 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound
    iii. Prior peripheral artery (excluding carotid) revascularisation procedure
    iv. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis).
    - eGFR ≥ 15 i < 60 mL/min/1.73 m2 (izračunato prema the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) jednadžbi kreatinina)
    - HsCRP ≥ 2 mg/L na probiru (posjet 1)
    - Dokazana ASCVD-a (aterosklerotska kardiovaskularna bolest) jednim ili više od sljedećih parametara:
    a) Koronarna bolest srca definirana najmanje jednim od sljedećih:
    i. Dokumentirani infarkt miokarda
    ii. Prethodni postupak koronarne revaskularizacije
    iii. ≥ 50% stenoze u velikoj epikardijalnoj koronarnoj arteriji dokumentirano kateterizacijom srca ili CT koronarografijom
    b) Cerebrovaskularna bolest definirana najmanje jednim od sljedećih:
    i. Prethodni moždani udar aterosklerotskog podrijetla
    ii. Prethodni postupak revaskularizacije karotidne arterije
    iii. ≥ 50% stenoze karotidne arterije dokumentirane rendgenskom angiografijom, MR angiografijom, CT angiografijom ili Doppler ultrazvukom.
    c) Simptomatska bolest perifernih arterija (PAD) definirana najmanje jednim od sljedećih:
    i. Intermitentna klaudikacija s gležanj-brahijalnim indeksom (ABI) ≤ 0,90 u mirovanju
    ii. Intermitentna klaudikacija sa ≥50% stenoze u perifernoj arteriji (isključujući karotidu) dokumentirana rendgenskom angiografijom, MR angiografijom, CT angiografijom ili Doppler ultrazvukom
    iii. Prethodni postupak revaskularizacije periferne arterije (isključujući karotide)
    iv. Amputacija donjih ekstremiteta na ili iznad gležnja zbog aterosklerotske bolesti (isključujući npr. traumu ili osteomijelitis)
    E.4Principal exclusion criteria
    - Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
    - Myocardial infarction, stroke, hospitalisation for unstable angina pectoris, or transient ischaemic attack within 60 days prior to randomisation (visit 2).
    - Planned coronary, carotid or peripheral artery revascularisation known on the day of screening (visit 1).
    - Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2).
    -Klinički dokazi ili sumnja na aktivnu infekciju prema procjeni liječnika ispitivača
    - Infarkt miokarda, moždani udar, hospitalizacija zbog nestabilne angine pektoris ili prolaznog ishemijskog napada unutar 60 dana prije randomizacije (posjet 2).
    - Planirana revaskularizacija koronarnih, karotidnih ili perifernih arterija poznata na dan pregleda (posjet 1)
    - Veći kardiokirurški, nekardijalni kirurški ili veliki endoskopski zahvat (torakoskopski ili laparoskopski) unutar zadnjih 60 dana prije randomizacije (posjet 2), ili bilo koji veći kirurški zahvat planiran u vrijeme randomizacije (posjet 2)
    E.5 End points
    E.5.1Primary end point(s)
    1. Time to first occurrence of 3-point MACE, a composite endpoint consisting of:
    - CV death ( Based on EAC-confirmed events, including undetermined cause of death)
    - non-fatal MI ( Based on EAC-confirmed events, acute MI only)
    - non-fatal stroke ( Based on EAC-confirmed events, including ischaemic, haemorrhagic and undetermined stroke)
    1. Vrijeme do prvog pojavljivanja MACE-a (velikog štetnog kardiovaskularnog događaja). Ova primarna krajnja točka sastoji se od sljedeće 3 točke:
    • Kardiovaskularna smrt (temeljeno na EAC potvrđenim događajima, uključujući neodređen uzrok smrti)
    • Infarkt miokarda koji nema smrtni ishod (temeljeno na EAC potvrđenim događajima, samo akutni infarkt miokarda)
    • Moždani udar koji nema smrtni ishod (temeljeno na EAC potvrđenim događajima, uključujući ishemijski, hemoragijski i neodređeni uzrok moždanog udara)
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. From randomisation (month 0) to end-of-study (up to 48 months (Maximum treatment duration is dependent on event rates and is estimated to be approximately 48 months including a 3-month follow-up period)
    1. od randomizacije (0-ti mjesec) do kraja ispitivanja (do 48 mjeseci) (Maksimalno trajanje ispitivanja ovisi o prikupljenom broju događaja i procjenjuje se na približno 48 mjeseci uključujući 3-mjesečno razdoblje praćenja )
    E.5.2Secondary end point(s)
    1. Time to first occurrence of expanded MACE, a composite endpoint consisting of:
    - CV death (Based on EAC-confirmed events, including undetermined cause of death)
    - non-fatal MI ( Based on EAC-confirmed events, acute MI only)
    - non-fatal stroke ( Based on EAC-confirmed events, including ischaemic, haemorrhagic and undetermined stroke)
    - hospitalisation for unstable angina pectoris requiring urgent coronary revascularisation ( Based on EAC-confirmed events)
    2. Number of hospitalisations for heart failure (Based on EAC-confirmed events) or urgent heart failure visit (Based on EAC-confirmed events)
    3. Time to occurrence of all-cause mortality (Based on EAC-confirmed events)
    4. Time to first occurrence of a composite CKD endpoint consisting of:
    - onset of persistent (“Persistent” is defined as 2 consecutive samples meeting the criteria. The 2 samples must be at least 4 weeks apart) greater than or equal to 40% reduction in eGFR (CKD-EPI) compared with baseline
    - kidney failure defined as:
    a) death from kidney failure (Based on EAC-confirmed events, defined as a non-CV death that is due to the direct consequences of severely impaired kidney function. Undetermined cause of death in participants with eGFR below15 mL/min/1.73 m^2 will be considered kidney death)
    b) onset of persistent (“Persistent” is defined as 2 consecutive samples meeting the criteria. The 2 samples must be at least 4 weeks apart) eGFR below 15 mL/min/1.73 m^2 (CKD-EPI)
    c) initiation of chronic kidney replacement therapy (maintenance dialysis or kidney transplantation) (Based on EAC-confirmed events)
    5. Time to first occurrence of each of the individual components (Based on EAC-confirmed events) of the expanded MACE endpoint and the kidney composite endpoint
    6. Time to first occurrence of MIs (acute MI only) (fatal and non-fatal) (Based on EAC-confirmed events)
    7. Time to first occurrence of stroke (including ischaemic, haemorrhagic and undetermined stroke) (fatal and non-fatal) (Based on EAC-confirmed events)
    8. Time to first occurrence of a composite MACE endpoint consisting of:
    - all-cause mortality (Based on EAC-confirmed events)
    - non-fatal MI (Based on EAC-confirmed events, acute MI only),
    - non-fatal stroke (Based on EAC-confirmed events, including ischaemic, haemorrhagic and undetermined stroke)
    9. Time to first occurrence of an expanded composite kidney endpoint consisting of:
    - CV death (Based on EAC-confirmed events, including undetermined cause of death)
    - onset of persistent (“Persistent” is defined as 2 consecutive samples meeting the criteria. The 2 samples must be at least 4 weeks apart) greater than or equal to 40% reduction in eGFR (CKD-EPI) compared with baseline
    - kidney failure defined as:
    a) death from kidney failure (Based on EAC-confirmed events, defined as a non-CV death that is due to the direct consequences of severely impaired kidney function. Undetermined cause of death in participants with eGFR below 15 mL/min/1.73 m^2 will be considered kidney death)
    b) onset of persistent (“Persistent” is defined as 2 consecutive samples meeting the criteria. The 2 samples must be at least 4 weeks apart) eGFR below 15 mL/min/1.73 m^2 (CKD-EPI)
    c) initiation of chronic kidney replacement therapy (maintenance dialysis or kidney transplantation)(Based on EAC-confirmed events)
    10. Time to first occurrence of coronary revascularisation
    11. Change in UACR
    12. Change in eGFR (CKD-EPI)
    13. Annual rate of change in eGFR (CKD-EPI) (total eGFR slope)
    14. Change in hs-CRP
    15. Change in NT-pro-BNP
    16. Change in left ventricular ejection fraction (LVEF)
    17. Number of events of atrial fibrillation
    18. Number of hospitalisations with infection as primary cause (Based on EAC-confirmed events) or death due to infection (Based on EAC-confirmed events)
    19. Change in Short Form 36 (SF-36) Physical Component Score (PCS)
    1. Vrijeme do prvog pojavljivanja MACE-a (velikog štetnog kardiovaskularnog događaja). Ova krajnja točka sastoji se od sljedeće 3 točke:
    o kardiovaskularna smrt (temeljeno na EAC potvrđenim događajima, uključujući neodređen uzrok smrti)
    o infarkt miokarda koji nema smrtni ishod (temeljeno na EAC potvrđenim događajima, samo akutni infarkt miokarda)
    o moždani udar koji nema smrtni ishod (temeljeno na EAC potvrđenim događajima, uključujući ishemijski, hemoragijski i neodređeni uzrok moždanog udara)
    o hospitalizacija zbog nestabilne angine pektoris što zahtjeva hitnu koronarnu revaskularizaciju (temeljeno na EAC potvrđenim događajima)
    2. Broj hospitalizacija kod zatajenja srca (temeljeno na EAC potvrđenim događajima) ili prijma na hitnu zbog srčanog zatajenja (temeljeno na EAC potvrđenim događajima)
    3. Vrijeme pojavljivanja mortaliteta različitog uzroka (temeljeno na EAC potvrđenim događajima)
    4. Vrijeme do prvog pojavljivanja CKD (Chronic kidney disease) krajnje točke:
    o početak perzistentne redukcije eGRF ≥ 40% u usporedbi s vrijednošću od početka ispitivanja ("Perzistentno" se definira kao 2 uzastopna uzorka koji ispunjavanju kriterije. Razmak između dva uzorka mora biti najmanje 4 tjedna)
    o zatajenje bubrega definirano kao:
    a) smrt od zatajenja bubrega (Na temelju događaja koje je EAC potvrdio, definirano kao ne-KV smrt koja je posljedica izravnih teških poremećaja funkcije bubrega. Uzrok smrti ispitanika s eGFR < 15 ml/min/1,73 m^2 smatrat će se definitivno bubrežno zatajenje)
    b) početak perzistentne kronićne bolesti bubrega (eCFR< 15 ml/min/1.73 m2) ("Perzistentno" se definira kao 2 uzastopna uzorka koji ispunjavanju kriterije. Razmak između dva uzorka mora biti najmanje 4 tjedna)
    c) početak kronične nadomjesne bubrežne terapije (dijaliza ili transplantacija bubrega) (Na temelju događaja potvrđenih od strane EAC-a)
    5. Vrijeme do prvog pojavljivanja svake pojedinačne komponente (na temelju EAC-potvrđenim događaja) proširene krajnje točke MACE i kompozitna krajnja točka bubrega
    6. Vrijeme do prve pojave MI (samo akutni MI) (fatalni i nefatalni) (Na temelju događaja koje je potvrdio EAC)
    7. Vrijeme do prve pojave moždanog udara (uključujući ishemijski, hemoragijski i neodređen uzrok moždanog udara) (fatalan i nefatalan) (temeljeno na EAC potvrđenim događajima)
    8. Vrijeme do prvog pojavljivanja kompozitne MACE krajnje točke koja se sastoji od:
    - smrtnost bilo kojeg uzroka (Na temelju EAC-a potvrđenih događaja)
    - nefatalni MI (Na temelju EAC potvrđenih događaja, samo akutni MI),
    - nefatalni moždani udar (Na temelju EAC potvrđenih događaja, uključujući ishemijski,hemoragijski i moždani udar neodređenog uzroka)
    9. Vrijeme do prve pojave proširene kompozitne krajnje točke bubrega koja se sastoji od:
    - kardiovaskularne smrti (Na temelju EAC-a potvrđenih događaja, uključujući neodređene
    uzroke smrti)
    - početak perzistentnosti ("Perzistentno" se definira kao 2 uzastopna uzorka ispunjavanje kriterija. Razmak između dva uzorka mora biti najmanje 4 tjedna) veće ili jednako 40% smanjenju eGFR (CKD-EPI) u usporedbi s osnovnom linijom
    - zatajenje bubrega definirano kao:
    a) smrt od zatajenja bubrega (na temelju EAC potvrđenih događaja, definirano kao ne-KV smrt koja je zbog izravnih posljedica teških poremećaja funkcije bubrega. Neodređen uzrok smrti ispitanika s eGFR ispod 15 mL/min/1,73 m^2 smatrat će se bubrežnom smrću)
    b) početak perzistentnosti ("Perzistentno" se definira kao 2 uzastopna uzorka ispunjavanje kriterija. Razmak između dva uzorka mora biti najmanje 4 tjedna) eGFR ispod 15 mL/min/1,73 m^2 (CKD-EPI)
    c) početak kronične nadomjesne bubrežne terapije (dijaliza ili transplantacija bubrega) (Na temelju EAC-a potvrđenih događaja)
    10. Vrijeme do prve pojave koronarne revaskularizacije
    11. Promjena UACR-a
    12. Promjena eGFR (CKD-EPI)
    13. Godišnja stopa promjene eGFR (CKD-EPI) (ukupni nagib eGFR)
    14. Promjena hs-CRP
    15. Promjena u NT-pro-BNP
    16. Promjena ejekcijske frakcije lijeve klijetke (LVEF)
    17. Brojepizoda fibrilacije atrija
    18. Broj hospitalizacija s infekcijom kao primarnim uzrokom (Na temelju EAC potvrđenih događaja) ili smrt zbog infekcije (Na temelju EAC potvrđenih događaji)
    19. Promjena u upitniku 36 (SF-36) Ocjena fizičke komponente (PCS)
    E.5.2.1Timepoint(s) of evaluation of this end point
    1.- 10. From randomisation (month 0) to end-of-study (up to 48 months (Maximum treatment duration is dependent on event rates and is estimated to be approximately 48 months including a 3-month follow-up period.))
    11.- 12. From randomisation (month 0) to (24 months)
    13. From randomisation (month 0) to end-of-study (up to 48 months (Maximum treatment duration is dependent on event rates and is estimated to be approximately 48 months including a 3-month follow-up period.))
    14.- 16. From randomisation (month 0) to (24 months)
    17.-18. From randomisation (month 0) to end-of-study (up to 48 months (Maximum treatment duration is dependent on event rates and is estimated to be approximately 48 months including a 3-month follow-up period.))
    19. From randomisation (month 0) to (24 months)
    1.- 10. Od randomizacije (mjesec 0) do završetka ispitivanja (do 48 mjeseci) (Maksimalno trajanje ispitivanja ovisi o broju prikupljenih događaja,procjenjuje se na približno 48 mjeseci uključujući 3-mjesečno razdoblje praćenja)
    11.- 12. Od randomizacije (mjesec 0) do (24 mjeseca)
    13. Od randomizacije (mjesec 0) do završetka ispitivanja (do 48 mjeseci)
    14.- 16. Od randomizacije (mjesec 0) do (24 mjeseca)
    17.-18. Od randomizacije (mjesec 0) do kraja ispitivanja (do 48 mjeseci) (Maksimalno trajanje ispitivanja ovisi o broju prikupljenih događaja događaja i procjenjuje se na približno 48 mjeseci uključujući 3-mjesečno razdoblje praćenja)
    19. Od randomizacije (mjesec 0) do (24 mjeseca)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Podnošljivost
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA191
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Brazil
    Canada
    China
    India
    Israel
    Japan
    Korea, Republic of
    Malaysia
    Mexico
    South Africa
    Taiwan
    United States
    European Union
    Russian Federation
    Turkey
    Ukraine
    United Kingdom
    Serbia
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days14
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days14
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1250
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 4950
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 2134
    F.4.2.2In the whole clinical trial 6200
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    none
    none
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-12-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-08-04
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 07:10:48 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA